Needham Maintains Buy on Biogen, Raises Price Target to $256

Benzinga Newsdesk www.benzinga.com Positive 77.4%

Neg 0% Neu 0% Pos 77.4%

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.

Comments

No comments yet. Be the first!